Reviewing the Inability of Anti-Amyloid Immunotherapies to Affect Alzheimer's Disease (opens in new tab)

In the context of Alzheimer's disease, the data for anti-amyloid immunotherapies, the most recent of which do effectively clear the aggregation of amyloid-β in the brain, is not compelling. Clinical trials and following studies show minimal to no benefit to patients even at earlier stages of the condition. There is some hope in the research and development community, where the amyloid cascade hypothesis remains dominant, that moving to even earlier deployment of these therapies might prevent ...